Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines

BACKGROUND: Phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway is a therapy target of cancer. We aimed to confirm the effect of dual PI3K/mTOR inhibitor NVP-BEZ235 on proliferation, apoptosis, and autophagy of chronic myelogenous leukemia (CML) cells and sensitiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Xin, Pengliang, Li, Chuntuan, Zheng, Yan, Peng, Qunyi, Xiao, Huifang, Huang, Yuanling, Zhu, Xiongpeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5388256/
https://www.ncbi.nlm.nih.gov/pubmed/28435223
http://dx.doi.org/10.2147/DDDT.S132092

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5388256/
https://www.ncbi.nlm.nih.gov/pubmed/28435223
http://dx.doi.org/10.2147/DDDT.S132092

Ejemplares similares